Table 5.

Safety profile of the patients with or without viable HCC

	HCC (+) (n=38)	HCC (−) (n=675)	P value
Drug discontinuation, n (%)	4 (10.5)	19 (2.8)	0.03
Mortality, n (%)	2 (5.3)	1 (0.1)	0.008
Serious adverse event, n (%)	4 (10.5)	7 (1.0)	0.002
Adverse event, n (%)	13 (34.2)	230 (34.1)	0.99
Fatigue, n (%)	7 (18.4)	80 (11.9)	0.21
Nausea/vomiting, n (%)	0 (0)	12 (1.8)	1
Headache, n (%)	1 (2.6)	47 (7.0)	0.51
Pruritus, n (%)	5 (13.2)	106 (15.7)	0.82
Rash, n (%)	2 (5.3)	39 (5.8)	1
Insomnia, n (%)	5 (13.2)	100 (14.8)	1
Dyspnoea, n (%)	4 (10.5)	23 (3.4)	0.05

HCC, hepatocellular carcinoma.